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There is growing consensus that intervention and treatment of Huntington disease (HD)
should occur at the earliest stage possible. Various early-intervention methods for this fatal
neurodegenerative disease have been identified, but preventive clinical trials for HD are
limited by a lack of knowledge of the natural history of the disease and a dearth of appro-
priate outcome measures. Objectives of the current study are to document the natural
history of premanifest HD progression in the largest cohort ever studied and to develop
a battery of imaging and clinical markers of premanifest HD progression that can be used
as outcome measures in preventive clinical trials. Neurobiological predictors of Hunting-
ton’s disease is a 32-site, international, observational study of premanifest HD, with annual
examination of 1013 participants with premanifest HD and 301 gene-expansion negative
controls between 2001 and 2012. Findings document 39 variables representing imaging,
motor, cognitive, functional, and psychiatric domains, showing different rates of decline
between premanifest HD and controls. Required sample size and models of premanifest
HD are presented to inform future design of clinical and preclinical research. Preventive
clinical trials in premanifest HD with participants who have a medium or high probability of
motor onset are calculated to be as resource-effective as those conducted in diagnosed
HD and could interrupt disease 7–12 years earlier. Methods and measures for preventive
clinical trials in premanifest HD more than a dozen years from motor onset are also fea-
sible. These findings represent the most thorough documentation of a clinical battery for
experimental therapeutics in stages of premanifest HD, the time period for which effective
intervention may provide the most positive possible outcome for patients and their families
affected by this devastating disease.
Keywords: Huntington disease, neurodegenerative disorders, premanifest, natural history, clinical trials, outcome
measures, PREDICT-HD
INTRODUCTION
Since 2001, Neurobiological Predictors of Huntington’s Disease
(PREDICT-HD; NS040068) has examined early indicators of
disease in over 1300 participants at risk for Huntington disease
(HD). Previous publications documented motor, cognitive, psy-
chiatric, and imaging correlates of emerging disease (Paulsen et al.,
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2006, 2008; Duff et al., 2007; Biglan et al., 2009). The discovery
that changes due to HD begin many years prior to the onset of
diagnosable HD has fostered growing consensus that intervention
at the earliest possible phase is desirable. Experimental pharma-
cologic interventions are currently being tested and methods to
silence the polyglutamine gene expansion are underway (Zhang
et al., 2009; Ross and Tabrizi, 2011). Significant limitations to pre-
ventive clinical trials for HD include a lack of knowledge of the
natural history of the disease and a dearth of outcome measures
sensitive to disease changes in the earliest, or premanifest, stages
of the disease.
To date, longitudinal studies have documented changes for
12, 24, and 36 months in smaller samples of premanifest HD
(Tabrizi et al., 2013). Changes have been demonstrated in basal
ganglia brain volumes (Aylward et al., 2011; Majid et al., 2011) and
declines in cognitive performance, primarily emphasizing speeded
cognitive processing (Kirkwood et al., 1999; Paulsen et al., 2001,
2013; Lemiere et al., 2002; Maroof et al., 2011), executive function
(Snowden et al., 2002; Rupp et al., 2010; O’Rourke et al., 2011; Papp
et al., 2013), working memory (Lemiere et al., 2004), visuomotor
control (Hart et al., 2011; Tabrizi et al., 2012, 2013), and time pro-
duction (Rowe et al., 2010). To our knowledge, only one other
study has examined multiple phenotypic and biologic markers of
change over time together in premanifest HD (Tabrizi et al., 2012,
2013). Conclusions from this group suggest imaging measures are
useful for indexing change, but “decline in cognitive, quantitative
motor, or oculomotor measures were limited at this stage” (Tabrizi
et al., 2012).
The aims of the study are twofold. First, we aim to document the
natural history of premanifest HD progression in the largest cohort
ever studied. Second, we aim to develop a battery of imaging and
clinical markers of premanifest disease progression. Findings are
interpreted in terms of their utilitarian value for preventive clini-
cal trials. Outcome measures are scaled to facilitate comparisons,
and hypothesized effect sizes are used to determine sample sizes
for randomized clinical trials (RCTs). Finally, graphical analysis is
used to illustrate the course of premanifest HD.
MATERIALS AND METHODS
PARTICIPANTS
Data in this study were collected from September 2001 to August
2012 from N = 1314 PREDICT-HD participants (1013 with pre-
manifest HD and 301 controls) at 32 worldwide sites. All par-
ticipants had completed genetic testing for HD prior to (and
independent from) study enrollment. Participants with>35 CAG
expansion repeats in the HTT gene were cases and those with
repeats<36 served as gene-mutation negative comparison partic-
ipants (controls). Exclusion criteria included other central nervous
system disease, injury, or developmental disorder, or evidence of
an unstable medical or psychiatric illness. The research protocol
was approved by each site’s respective institutional review board
and ethics committee, and all participants gave written informed
consent and were treated in accordance with ethical standards.
Average years in the study (median) were six, with a range of
1–10. Over 75% of the sample had more than 3 years of data col-
lected, 15% had 2 years, and<10% had 1 year. A subset of N= 204
gene-expanded participants received a motor diagnosis during the
study (referred to as “converters”). Dropout was less than 5%
per year. Sample size variation was due to a number of historic
study design events: 1) the National Institutes of Health (NIH)
grant that funded the study was renewed three times and partici-
pants were recruited for the duration of each individual grant; and
2) grant reviewers increased sample size on each renewal, so the
total sample size increased as the length of possible study duration
decreased.
PREMANIFEST STAGING GROUPS: CAG-AGE PRODUCT
Premanifest stages were based on a formula using genetic and
demographic information to estimate proximity to HD diagnosis.
The CAG-Age Product (CAP) score, computed as CAPE= (age
at entry)× (CAG− 33.66) (Zhang et al., 2011), was derived from
an accelerated failure time (AFT) model predicting motor diag-
nosis from age at entry, CAG length, and their interaction. CAPE
is similar to the “disease burden” score of Penney et al. (1997)
and presumably indexes the cumulative toxicity of mutant hunt-
ingtin. CAPE can also be used to estimate the 5-year probability
of motor diagnosis. Cutoffs for groups were CAPE < 290 (Low),
290≤CAPE≤ 368 (Medium), and CAPE > 368 (High). The esti-
mated time to diagnosis was, respectively,>12.78, 7.59–12.78, and
<7.59 years. A dynamic (time-varying) CAP score was also used,
denoted as CAPD, and computed with current age (rather than
age at entry). CAPD can be interpreted as a type of CAG-adjusted
age metric (Ross et al., 2014). Table 1 shows descriptive statistics
for demographic variables by premanifest groups defined at study
entry (i.e., based on CAPE).
STATISTICAL ANALYSIS
The main analysis focused on change over time in each premanifest
group controlling for covariates (age, education, gender, depressed
mood severity, brain scanner field strength). Interest was in the
comparison of premanifest and control groups. Using linear mixed
effects regression (LMER) (Verbeke and Molenberghs, 2000), 39
variables of interest were analyzed separately. Detailed descrip-
tions of the variables are provided in the Supplementary Material.
To control for site-to-site variability, a three-level model was used
with repeated measures nested within participants, nested within
Table 1 | Demographic variables for progression groups.
Controla Low Medium High
N 301 283 358 372
Female 194 (64.45%) 190 (67.14%) 235 (65.64%) 218 (58.60%)
Age 44.36 (11.41) 34.98 (7.92) 41.67 (9.56) 44.93 (10.09)
Education 14.87 (2.56) 14.57 (2.44) 14.54 (2.61) 14.33 (27.5)
Years in
study
4.39 (2.29) 4.41 (2.68) 4.64 (2.61) 4.98 (2.52)
CAG 20.27 (3.49) 40.91 (1.62) 42.02 (2.04) 43.58 (2.74)
CAPE NA 243.97 (34.55) 330.50 (23.05) 423.19 (51.25)
Converters NA 11 (3.89%) 49 (13.69%) 144 (38.71%)
aPercentage is based on group total. CAG, cytosine–adenine–guanine expansion;
CAPE = (age at entry)× (CAG−33.66). Mean (SD) is presented for a continuous
variable and frequency (percentage) for a categorical or count variable.
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sites. A preliminary analysis not presented showed evidence that
linear curves were adequate for the modeling of change over time
stratifying on CAPE group. Random intercepts and slopes were
specified for participants, as well as for sites. The time metric for
the analysis was duration in the study (years in the study) with
0= study entry. Two models were estimated for each outcome
variable, a null model of duration and covariates only, and a full
model adding CAPE group intercept and slope differences. Max-
imum likelihood (ML) methods were used for estimation, which
yield unbiased estimates under the widely-applicable assumption
that the missing data mechanism is ignorable (Little and Rubin,
2002). The two models (null, full) were compared using the like-
lihood ratio test (LRT), which evaluates the null hypothesis that
two nested models are statistically equivalent. The LRT statistic
can be treated as an effect size measure in this case because the
degrees of freedom are constant for each model test, and the out-
come variables were rank-ordered according to the LRT statistic.
To facilitate comparisons among the outcome variables, the esti-
mated slopes from the LMER analysis were expressed in standard
deviation (SD) units. To produce these estimates, each outcome
was scaled using the grand mean and SD prior to the LMER analy-
sis. Interest was in the comparison of premanifest and control
groups. Z -tests of slope differences were computed as the esti-
mated difference divided by its standard error. The control group
Z -test was a test against a zero slope value. Three ancillary analy-
ses were conducted. The first analysis examined possible effects
of conversion. The second focused on required sample size for a
hypothetical RCT. The third was a graphical analysis of trends over
all progression periods for eight of the key variables. Variables were
chosen conceptually to represent the phenotypic characteristics of
HD (motor, cognitive, psychiatric) as well as to represent biologi-
cal (imaging) and functional outcomes. Details of all analyses are
presented in the Supplementary Material.
RESULTS
Table 2 shows the LMER results. The variables with the largest
effect sizes (LRT statistics) were imaging measures based on
regional brain volumes (corrected for intra-cranial volume and
controlled for change in field strength). The two top-ranked mea-
sures were the putamen and caudate structure volumes. The slopes
for the controls showed significant decrease over time (consis-
tent with normal aging), but the decline in the gene-expansion
groups steadily decreased over time for all groups. The slope for
each premanifest group was statistically different from the Con-
trol group (all ps< 0.001). Other imaging variables demonstrating
significant change relative to controls included accumbens, cere-
bral spinal fluid (CSF), lobar gray, hippocampus, and lobar white
(though only for the High group). The putamen, caudate, CSF, and
lobar gray measures showed significant longitudinal change in all
three premanifest groups. A graphical depiction of change in brain
volume for the groups is shown in Figure S1 in Supplementary
Material.
Total motor score (TMS) from the Unified Huntington’s Dis-
ease Rating Scale (UHDRS) showed the next highest effect size
in change rates over time (rank four). The Control group slope
was not statistically different from zero, and the Low group slope
was not statistically different from the Control group slope. The
Medium group slope was significantly larger than the Control
slope, as was the High slope (all ps< 0.001). The next strongest
effects were for bradykinesia (rank five) and chorea (rank six).
Decline in cognitive performance was significant in every mea-
sure examined. Symbol Digit Modality Test (SDMT) had the
seventh-strongest effect over all measures. The Control group
slope was positive and significantly greater than zero, indicating
a practice effect. The Low group slope was negative and worse
than the Control group slope. The Medium slope showed greater
decline than the Low slope, and the High slope showed even
greater decline. All cognitive measures examined showed signif-
icant changes in the High group, and 9 of 10 cognitive measures
showed significant change in the Medium group. Four cognitive
measures (SDMT, Stroop–word, Smell–ID, and the Trail Making
Test) showed significant change over time in the Low group.
Regarding the functional variables, every measure examined
showed significant change over time compared with the controls,
except for the participant-rated World Health Organization Dis-
ability Assessment Schedule (WHODAS). The total functional
capacity (TFC) scale (rank 20) showed the largest effect in the
High group. The Control group slope and the Low group slope
were not statistically different than zero. The Medium group slope
showed significant decline, and the High group slope even more so.
Though the Everyday Cognition Rating Scale (ECog) companion
total had a weaker effect size (rank 26), the Low group was statisti-
cally different than the Control group, as were the higher progres-
sion groups. Four of the six functional measures showed robust
change in the Medium group and three showed change in the Low
group. The functional measures most appropriate for the different
stages of premanifest HD varied. Whereas the TFC showed the
greatest effect size in the High group, the companion WHODAS
and ECog showed greater change in the Medium and Low groups.
Eight of the nine psychiatric variables showed significant
change over time relative to controls. The SCL-90 obsessive–
compulsive scale had the strongest effect (rank 22). There was
an increase in obsessive–compulsive signs over time as the pro-
gression group increased (Control through High). Frontal Sys-
tems Behavioral Scale (FRSBE) executive and apathy subscales,
ranked 24 and 25, respectively, also showed robust effect sizes.
Seven of nine measures showed significant change in the Medium
group and one psychiatric measure (FRSBE disinhibition) showed
significant longitudinal change in the Low group.
Table 3 shows the six variables that had a statistically significant
acceleration of the slope for the participants who converted. The
fourth column (acceleration) shows the value added to a slope in
Table 2 to indicate the additional deterioration associated with
conversion. The variables are sorted by proportionate increase,
with dystonia having the largest change under conversion (approx-
imately 2.1 times faster decline). The acceleration factor is most
applicable for the High group because the largest proportion of
conversion occurred in this group (see Table 1). The acceleration
factors ranged from a mild added slope acceleration of 0.06 SD
per year for TMS, to a strong acceleration of 0.20 SD per year for
dystonia.
Table 4 shows the single-group estimated sample size as a func-
tion of dropout percentage, effect size, and estimated parameters
for a hypothetical RCT of efficacy consistent with guidelines for
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Table 2 | Linear mixed effects regression results showing annual rate of change (slope) and rank-order based on effect size.
Variable Type N N* Progression group LRT Rank
Control Low Medium High
Putamen Imaging 1206 2845 −0.0407*** −0.0900*** −0.1122*** −0.1119*** 714.38*** 1
Caudate Imaging 1207 2846 −0.0331** −0.0769*** −0.1028*** −0.1192*** 515.33*** 2
Accumbens Imaging 1207 2846 −0.0264 −0.0279 −0.0853*** −0.1110*** 417.38*** 3
CSF Imaging 1205 2840 0.0511*** 0.0804** 0.1021*** 0.0978*** 223.19*** 11
Lobar gray Imaging 1175 2768 −0.0874*** −0.1220** −0.1293*** −0.1523*** 125.23*** 19
Hippocampus Imaging 1206 2845 −0.0337** −0.0275 −0.0626** −0.0910*** 98.33*** 23
Lobar white Imaging 1149 2680 0.0223 0.021 0.0122 −0.0220*** 63.73*** 29
Thalamus Imaging 1204 2843 −0.0327* −0.0217 −0.0362 −0.0487 18.69** 39
TMS Motor 1308 6077 0.0016 0.0332 0.0933*** 0.2397*** 415.75*** 4
Chorea Motor 1310 6124 0.0028 0.0395 0.0935*** 0.2430*** 332.72*** 5
Brady Motor 1308 6102 −0.003 0.0297 0.0790*** 0.2063*** 331.14*** 6
Ocular Motor 1309 6124 0.0008 0.0097 0.0683*** 0.1397*** 293.61*** 8
Dystonia Motor 1310 6130 −0.0009 0.0295 0.0524* 0.1698*** 114.56*** 21
Rigidity Motor 1310 6127 0.0203 0.0406 0.028 0.0744*** 38.58** 36
SDMT Cognitive 1230 5252 0.0287** −0.0012** −0.0336*** −0.0800*** 303.63*** 7
Dysrhythmia Cognitive 969 2270 −0.0107 −0.0089 0.0468* 0.1279*** 236.60*** 9
Stroop-Co Cognitive 1228 5246 0.0327*** 0.0103 −0.0284*** −0.0811*** 234.50*** 10
Stroop-Wo Cognitive 1228 5255 0.0056 −0.0201* −0.0416*** −0.0986*** 222.97*** 12
Sp-Tapping Cognitive 975 2278 0.0046 0.038 0.0629** 0.1476*** 214.97*** 13
Smell-ID Cognitive 1212 3745 0.0004 −0.0372* −0.0559*** −0.1283*** 189.31*** 14
TMT-B Cognitive 1221 3875 −0.02 0.0112 0.0188* 0.0878*** 178.52*** 15
Stroop-In Cognitive 1228 5245 0.0452*** 0.0252 0.0068** −0.0468*** 172.69*** 16
EmoRec Cognitive 978 2300 0.0342 0.049 0.0466 −0.0302** 163.05*** 17
TMT-A Cognitive 1223 3905 −0.0385* 0.0024* 0.0199** 0.1048*** 141.71*** 18
TFC Functional 1308 6140 −0.0184 −0.0443 −0.0870*** −0.2093*** 124.03*** 20
ECog-C Functional 795 1599 −0.0172 0.0469* 0.0576** 0.1074*** 68.24*** 26
ECog-P Functional 899 1928 −0.0228 0.0292* 0.0117 0.0408** 50.05** 32
FAS Functional 1052 4160 −0.0071 −0.0417 −0.0692* −0.1688*** 43.20*** 35
WHODAS-C Functional 708 1254 0.0105 0.0597 0.0859* 0.1193*** 37.56** 37
WHODAS-P Functional 769 1499 0.0199 0.0691 0.0522 0.0328 33.04** 38
S-OC-C Psychiatric 1236 5392 −0.0293* 0.0027 0.0175** 0.0649*** 100.54*** 22
F-Exc-C Psychiatric 1235 5288 −0.0226 −0.0036 0.0288** 0.0705*** 97.95*** 24
F-Apa-C Psychiatric 1235 5288 −0.0158 0.0131 0.0346** 0.0706*** 80.71*** 25
S-GSI-C Psychiatric 1237 5395 −0.0398*** −0.0096 −0.0016* 0.0404*** 66.53*** 27
S-Dep-C Psychiatric 1236 5392 −0.0391** −0.0054 −0.0048* 0.0352*** 65.15*** 28
S-Anx-C Psychiatric 1237 5393 −0.0339** −0.01 −0.0031* 0.0345*** 53.14*** 30
BDI Psychiatric 1042 4120 −0.0063 −0.0044 −0.04 0.0191 52.88** 31
F-Dis-C Psychiatric 1235 5288 −0.0219 0.0137* 0.0295*** 0.0575*** 49.57*** 33
S-Hos-C Psychiatric 1236 5392 −0.0256* −0.0208 −0.0063 0.0166** 46.45** 34
Imaging variables adjusted for baseline intra-cranial volume. N, sample size; N*, number of data points; LRT, likelihood ratio test statistic; *p<0.05, **p<0.01,
***p<0.001. Control p-value is a test against a zero slope and a CAP group p-value is a test against the Control slope. Progression Group (CAP group) is defined at
study entry (CAPe). Progression Group columns show the standardized annual rate of change (slope). Rank (last column) is based on the likelihood ratio test statistic.
CSF, cerebral spinal fluid; TMS, total motor score; Brady, bradykinesia; SDMT, Symbol Digit Modalities Test; Stroop-Co, Stroop Color and Word Test – color condition;
Stroop-Wo, Stroop Color and WordTest – word condition; SP-Tapping, speeded tapping; Smell-ID, University of Pennsylvania Smell IdentificationTest (UPSIT); TMT-B,
Trail Making Test, Part B; Stroop-In, Stroop Color and Word Test – interference condition; EmoRec, emotion recognition test; TMT-A, Trail Making Test, Part A; TFC,
total functional capacity; ECog-C, Everyday Cognition Rating Scale – Companion Rating Scale; ECog-P, Everyday Cognition Rating Scale – Participant Rating Scale;
FAS, functional activity scale; WHODAS-C, World Health Organization Disability Assessment Schedule – companion rating scale; WHODAS-P, World Health Orga-
nization Disability Assessment Schedule – participant rating scale; S-OC-C, Symptom Checklist 90–obsessive-compulsive scale – companion rating scale; F-Exc-C,
Frontal Systems Behavioral Scale – executive subscale – companion rating scale; F-Apa-C, Frontal Systems Behavioral Scale – apathy subscale – companion rating
scale; S-GSI-C, Symptom Checklist 90 – Global Severity Index – companion rating scale; S-Dep-C, Symptom Checklist 90 – depression subscale – companion rating
scale; S-Anx-C, Symptom Checklist 90 – anxiety subscale – companion rating scale; BDI, Beck Depression Inventory–II; F-Dis-C, Frontal Systems Behavioral Rating
Scale – disinhibition subscale – companion rating scale; S-Hos-C, Symptom Checklist 90 – hostility subscale – companion rating scale.
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Table 3 | Slope acceleration effect of motor diagnosis.
Variable Type Chisq Acceleration Increase
Dystonia Motor 91.77*** 0.191182 2.125979
Stroop-Co Cognitive 42.02*** −0.07891 1.973548
FAS Functional 26.80*** −0.15594 1.923999
SDMT Cognitive 29.57*** −0.06183 1.773312
TFC Functional 29.49*** −0.08748 1.417992
TMS Motor 22.20*** 0.055938 1.233343
*p<0.05, **p<0.01, ***p<0.001. Stroop-Co, Stroop Color and Word Test –
color condition; FAS, functional activity scale; SDMT, Symbol Digit ModalitiesTest;
TFC, total functional capacity; TMS, total motor score.
Phase II trials (The Lancet Neurology, 2012). Listed in the effect
size columns (20%, etc.) are the estimated required sample size.
Results are listed for variables that required N /2< 3000 for a 20%
effect and 20% dropout. CSF had the smallest single-group sample
size (e.g., N /2= 27 for a 70% effect with no dropout), followed
by putamen, caudate, TMS, speeded tapping, and additional vari-
ables. An approximate 70% difference in slopes was obtained in
a recent clinical efficacy trial for HD (Huntington Study Group,
2006). Sample sizes do not take into account change associated
with normal aging and thus may overestimate the effect sizes
for differences between treatment versus placebo groups for any
treatment that only addresses disease-related change.
Figure 1 shows curves of individual participants (thin colored
lines) and cubic spline curves (thick black lines) by premanifest
stage. For some of the variables, change was slower for earlier pre-
manifest stages but accelerated with proximity to average motor
onset value (vertical line) with a greater acceleration thereafter.
Figure 2 shows a model of disease progression for eight vari-
ables throughout the course of premanifest HD. The curves are
based on a cubic spline fit after standardizing each variable rela-
tive to controls. The imaging, cognitive, and psychiatric variables
showed linear increase over all premanifest stages, whereas motor
and functional variables tended to show a non-linear trajectory
with a sudden acceleration just prior to motor onset. Mean years
in the study were 6, with a range of 1–10. Over 75% of the sample
had >3 years of data, 15% had 2 years, and <10% had 1 year. A
subset of N = 204 gene-expanded participants received a motor
diagnosis during the study, referred to as “converters.” Dropout
was less than 5% per year. Sample size variation was due to a num-
ber of historic study design events: 1) the NIH grant that funded
the study was renewed three times and participants were recruited
for the duration of each individual grant; and 2) grant reviewers
increased sample size on each renewal, so the total sample size
increased as the length of possible study duration decreased.
DISCUSSION
Findings show longitudinal change in 36 of 39 measures exam-
ined over a 10-year natural observation study in premanifest HD.
Effect sizes suggest a preventive RCT could be efficiently designed
to detect treatment effects in the neighborhood of 30%, and effects
similar to the recent tetrabenazine efficacy trial (about 70% effect)
might be found with sample sizes near to 30 per arm, depend-
ing on the amount of dropout (Huntington Study Group, 2006).
Significant measures include each of the clinical phenotypic char-
acteristics of HD (motor, cognitive, psychiatric), as well as biologic
and functional outcomes. No previous study has so thoroughly
documented a clinical battery for experimental therapeutics in
stages of premanifest HD. Current findings dovetail with those
generated from smaller studies. Most importantly, the specific
measure chosen for each of the primary components typically
measured in HD is dependent upon the disease stage of the pre-
manifest cohort targeted for intervention. For example, the best
cognitive variable for a clinical trial in persons who are <8 years
to motor onset (High group) is tapping speed because it had the
largest significant absolute value standardized slope (=0.1476).
On the other hand, the most robust measure for tracking cogni-
tive change in persons who are more than a dozen years to onset
(Low group) is smell identification (see Table 2).
It is important to note that actual design of clinical trials
involves many factors. Trial design will need to balance feasi-
bility of cost-effective, multi-site research with the expense of
advanced technology methods that may limit resources and result
in fewer treatments being evaluated (Ross and Tabrizi, 2011). Ide-
ally, clinical trials for HD will involve intervention at multiple
and differing points along the cascade of changes that are known
to occur from gene expansion to patient suffering. Hence, inter-
ference with the disease processes could involve gene silencing,
altering posttranslational modifications of Huntington, ameliora-
tion of gene transcription abnormalities, or buttressing metabolic
abnormalities to thwart the devastation that people with HD and
their families endure. Different outcome measures may also have
different kinds of utility for Phase I versus Phase II trials or symp-
tomatic versus disease-modifying strategies. It is important to keep
in mind that the measurements listed in Table 4 do not take into
account changes related to normal aging. Changes in CSF vol-
ume, for example, are significant for premanifest participants but
also demonstrate relatively large effect sizes for controls. Thus, a
treatment that targets disease-related change, but not age-related
change, may be better evaluated with measures that are more sen-
sitive to longitudinal differences between premanifest cases versus
controls.
Much recent attention has been devoted to the importance of
natural history studies in the design of clinical trials1. In HD
literature, several authors have developed conceptual models of
natural history of the disease. None of the models are based on
actual data, however (see text footnote 1). Findings from this study
were used to develop a natural history model that is based on up
to 10 years of natural observation spanning a substantial range
of the premanifest period. The model can be used to develop
progression-based care guidelines as well as to design clinical
trials. Importantly, these data can provide external historical con-
trols facilitating single-treatment-group or dose-selection trials
without an active randomized placebo group (Elm et al., 2005;
Czaplinski et al., 2006). Figure 2 provides a data-driven model
1Workshop on Natural History Studies of Rare Diseases: meeting the Needs of
Drug Development and Research.” [U.S. Department of Health & Human Services,
National Institutes of Health and U.S. Food and Drug Administration workshop,
Bethesda, MD, USA May 16–17, 2012, https://events-support.com/events/Natural_
History_Studies/page/87]
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Table 4 | Estimated required sample size (right side) for a two-arm phase II randomized clinical trial.
Variable Type Dropout (%) Estimated parameters Effect size
βS g11 g12 g22 σ2e 20% 30% 40% 50% 60% 70%
CSF Imaging 0 4.094 486.882 5.189 3.183 53.737 332 147 83 53 37 27
CSF Imaging 10 4.094 486.882 5.189 3.183 53.737 357 159 89 57 40 29
CSF Imaging 20 4.094 486.882 5.189 3.183 53.737 386 172 97 62 43 32
Putamen Imaging 0 −0.100 0.810 −0.004 0.003 0.037 391 174 98 63 43 32
Putamen Imaging 10 −0.100 0.810 −0.004 0.003 0.037 421 187 105 67 47 34
Putamen Imaging 20 −0.100 0.810 −0.004 0.003 0.037 455 202 114 73 51 37
Caudate Imaging 0 −0.111 0.666 0.005 0.003 0.078 628 279 157 101 70 51
Caudate Imaging 10 −0.111 0.666 0.005 0.003 0.078 676 301 169 108 75 55
Caudate Imaging 20 −0.111 0.666 0.005 0.003 0.078 732 325 183 117 81 60
TMS Motor 0 1.498 21.338 5.008 3.050 16.789 981 436 245 157 109 80
TMS Motor 10 1.498 21.338 5.008 3.050 16.789 1051 467 263 168 117 86
TMS Motor 20 1.498 21.338 5.008 3.050 16.789 1131 503 283 181 126 92
Sp-Tapping Cognitive 0 7.345 3255.107 296.690 72.380 554.870 1230 546 307 197 137 100
Sp-Tapping Cognitive 10 7.345 3255.107 296.690 72.380 554.870 1318 586 330 211 146 108
Sp-Tapping Cognitive 20 7.345 3255.107 296.690 72.380 554.870 1421 632 355 227 158 116
Hippocampus Imaging 0 −0.022 0.066 0.000 0.000 0.006 1322 588 330 212 147 108
Hippocampus Imaging 10 −0.022 0.066 0.000 0.000 0.006 1422 632 356 228 158 116
Hippocampus Imaging 20 −0.022 0.066 0.000 0.000 0.006 1540 684 385 246 171 126
Chorea Motor 0 0.480 1.383 0.401 0.335 2.675 1373 610 343 220 153 112
Chorea Motor 10 0.480 1.383 0.401 0.335 2.675 1472 654 368 236 164 120
Chorea Motor 20 0.480 1.383 0.401 0.335 2.675 1586 705 397 254 176 130
Brady Motor 0 0.520 4.748 0.811 0.438 3.305 1467 652 367 235 163 120
Brady Motor 10 0.520 4.748 0.811 0.438 3.305 1574 699 393 252 175 128
Brady Motor 20 0.520 4.748 0.811 0.438 3.305 1698 754 424 272 189 139
Dysrhythmia Cognitive 0 3.002 592.124 53.942 12.919 135.291 1676 745 419 268 186 137
Dysrhythmia Cognitive 10 3.002 592.124 53.942 12.919 135.291 1801 800 450 288 200 147
Dysrhythmia Cognitive 20 3.002 592.124 53.942 12.919 135.291 1945 864 486 311 216 159
Thalamus Imaging 0 −0.058 0.316 −0.006 0.003 0.069 2077 923 519 332 231 170
Thalamus Imaging 10 −0.058 0.316 −0.006 0.003 0.069 2230 991 557 357 248 182
Thalamus Imaging 20 −0.058 0.316 −0.006 0.003 0.069 2407 1070 602 385 267 197
TFC Functional 0 −0.156 0.518 0.038 0.054 0.551 2540 1129 635 406 282 207
TFC Functional 10 −0.156 0.518 0.038 0.054 0.551 2722 1210 680 435 302 222
TFC Functional 20 −0.156 0.518 0.038 0.054 0.551 2932 1303 733 469 326 239
SDMT Cognitive 0 −0.906 124.336 0.742 0.904 20.943 2547 1132 637 408 283 208
SDMT Cognitive 10 −0.906 124.336 0.742 0.904 20.943 2740 1218 685 438 304 224
SDMT Cognitive 20 −0.906 124.336 0.742 0.904 20.943 2964 1317 741 474 329 242
Effect size is the percentage difference in rate of change (slope) of the treated and untreated groups (see Supplementary Material). CSF, cerebral spinal fluid; TMS,
total motor score; SP-Tapping, speeded tapping; Brady, bradykinesia; TFC, total functional capacity; SDMT, Symbol Digit Modalities Test.
of disease progression and illustrates progression using at least
one variable from each clinical domain (motor, cognitive, psychi-
atric), biological evidence of decline (imaging variables), as well as
a functional variable to encompass regulatory requirements. For
practical purposes we chose outcomes that illustrated the great-
est change for the High group, although the best choice for any
specific clinical trial will vary dependent upon the treatment, the
target and the premanifest cohort. For instance, the finding that
the TFC did not show change in the Low and Medium groups,
coupled with the sample sizes necessary to show a drug effect on
TFC in the High group suggests that this measure is not likely to
be an appropriate candidate for premanifest intervention in early-
phase trials (for Phase 3, the Food and Drug Administration [FDA]
wants to see a functional outcome). Efforts to provide a clinically
meaningful outcome (as requested by regulatory agencies) may
require consideration of other markers and extensive discussions
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FIGURE 1 | Plots of key outcome variables for preventive clinical
trials. Empirical individual curves (thin lines) and fitted spline curves
(thick lines) of key variables plotted over CAPD (CAG-corrected age).
Dashed lines indicate individuals who converted in the study. TMS
indicates total motor score; TFC, total functional capacity; SDMT,
Symbol Digit Modalities Test; Smell-ID, University of Pennsylvania
Smell Identification Test (UPSIT); Obsess-Comp, obsessive-compulsive;
CS Fluid, cerebral spinal fluid.
with regulators. Such findings have immediate implications for
current design of RCTs.
A primary strength of the PREDICT-HD study is that over 1300
gene-mutation-tested participants were prospectively followed up
to, and, for some, through the point of actual motor diagnosis.
Such data can be effective to document phenotypic and biologic
changes that occur in persons with the gene expansion over the
decade prior to, and, just after the manifestation of disease. Find-
ings suggest the course of biologic progression in premanifest HD
appears linear for imaging, cognitive, and psychiatric data, but
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FIGURE 2 | Data-derived model of premanifest Huntington disease.
Scaled fitted spline curves of key variables plotted over CAPD (CAG-corrected
age). Blue colors indicate variables that decrease and red colors indicate
variables that increase. Vertical axis is in standard deviation (SD) units. TMS
indicates total motor score; CSF, cerebral spinal fluid; DYS, dysrhythmia; O–C,
obsessive–compulsive; SDMT, Symbol Digit Modalities Test; SMELL,
University of Pennsylvania Smell Identification Test (UPSIT); TFC, total
functional capacity.
non-linear for motor and functional data (see Figure 2). Motor
expression appears to accelerate as the disease manifests over the
course of approximately 15 years prior to motor onset. It is impor-
tant to note that increases in the number and severity of clinical
outcomes reflect measurement aspects of the manifestation of dis-
ease and do not necessarily reflect a curvilinear, or increased, rate
of disease progression. One possible explanation may be that atro-
phy of each individual brain region (e.g., putamen as shown in
Figures 1 and 2) proceeds relatively linearly, but as additional
brain regions begin to undergo degeneration and dysfunction,
their combined effect causes acceleration of the clinical expression
of disease.
Additional strengths include the large, worldwide collabora-
tion among 32 sites and across brain scanners, cultures, and
languages, involving multiple disciplines and specialties. The
PREDICT-HD study may be most relevant to actual clinical tri-
als where multiple sites are likely to be used to acquire sufficient
sample sizes (The Lancet Neurology, 2012). Finally, the care
with which the study was conducted provides quality control,
quality assurances, standardization protocols, and statistical con-
trol for many common confounds (age, gender, education) and
not-so-common confounds (depressed mood, field strength). All
components of the study are shared worldwide to assure findings
can be replicated and utilized in the future as more knowledge
is acquired about HD and other neurodegenerative disorders,
so PREDICT-HD data can continue to facilitate progress for
decades onward.
Weaknesses also exist in the study. Interval to follow-up was
1 year for clinical and cognitive assessment and 2 years for imag-
ing, and clinical trials demand more frequent assessments. It is
recommended that the measures proposed be subjected to a brief
repeated measures study over a period of 6 months to assure that
more rapid assessment can be documented. Finally, due to the
length of the PREDICT-HD study, some protocol changes were
unavoidable. A common-but-important variation in our study
was the change in MRI scanners from 1.5 to 3 T. The basal gan-
glia structures were processed to accommodate this change, and
field strength was statistically controlled in the analysis. Solutions
to varying field strength and other methodological challenges of
PREDICT-HD can be made available to researchers who are inter-
ested in natural history studies. The lobar white matter measures
reported in this work incorporate data from much more heteroge-
neous data collection than were reported in previous publications.
The expanded subject inclusion for lobar white matter measures
included both the 1.5 and 3 T scanners from a larger number
of scanning sites. While the strength of white matter lobar mea-
sures is less than previously reported, we believe this is due to
inherent measurement variability introduced by heterogeneous
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data collection. Systematically addressing the variability due to
heterogeneous data collection is a focus of ongoing work.
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